Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 21, Issue 2, 2015, Pages 106-110

  Alcalay, Roy N ^a,b,h   Mejia Santana, Helen ^a   Mirelman, Anat ^c,d   Saunders Pullman, Rachel ^e,i   Raymond, Deborah ^e,i   Palmese, Christina ^e,i   Caccappolo, Elise ^a,b   Ozelius, Laurie ^f,i   Orr Urtreger, Avi ^c,g   Clark, Lorraine ^a,h   Giladi, Nir ^c,g   Bressman, Susan ^e,i   Marder, Karen ^a,b   Tang, Ming X ^h   Santana, Helen Mejia ^h   Roos, Ernest ^h   Orbe Reilly, Martha ^h   Fahn, Stanley ^h   Cote, Lucien ^h   Waters, Cheryl ^h   Mazzoni, Pietro ^h   Ford, Blair ^h   Louis, Elan ^h   Levy, Oren ^h   Rosado, Llency ^h   Ruiz, Diana ^h   Dorovski, Tsvyatko ^h   Greene, Paul ^h   Marder, Karen S ^h   Gurevich, Tanya ^g   Shira, Anat Bar ^g   GanaWeisz, Mali ^g   Yasinovsky, Kira ^g   Zalis, Maayan ^g   Thaler, Avner ^g   Balash, Yaacov ^g   Hertzel, Shabtai ^g   Gan, Ziv ^g   Kobo, Hila ^g   Hillel, Ariella ^g   Shkedy, Anat ^g   Deik, Andres ⁱ   Barrett, Matthew James ⁱ   Cabassa, Jose ⁱ   Groves, Mark ⁱ   Hunt, Ann L ⁱ   Lubarr, Naomi ⁱ   Luciano, Marta San ⁱ   Miravite, Joan ⁱ   Sachdev, Rivka ⁱ   Sarva, Harini ⁱ   Severt, Lawrence ⁱ   Shanker, Vicki ⁱ   Swan, Matthew Carrington ⁱ   Soto Valencia, Jeannie ⁱ   Johannes, Brooke ⁱ   Ortega, Robert ⁱ   more..

^a Columbia University ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ Beth Israel University Hospital   (United States)

Author keywords

Genetics; LRRK2; Neuropsychological tests; Parkinson

Indexed keywords

LEVODOPA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; ASHKENAZI JEW; ATTENTION; COGNITION; COMPARATIVE STUDY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PHENOTYPE; TASK PERFORMANCE; GENETICS; JEW; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

AGED; FEMALE; HETEROZYGOTE; HUMANS; JEWS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; PSYCHOMOTOR PERFORMANCE;

EID: 84921357548     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.09.033     Document Type: Article

References (34)

1. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7:583-590.
2. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., et al. LRRK2 G2019S as a cause of Parkinson's disease in ashkenazi jews. NEngl J Med 2006, 354:424-425.
3. Clark L.N., Wang Y., Karlins E., Saito L., Mejia-Santana H., Harris J., et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006, 67:1786-1791.
4. Alcalay R.N., Mejia-Santana H., Tang M.X., Rosado L., Verbitsky M., Kisselev S., et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009, 66:1517-1522.
5. Alves G., Larsen J.P., Emre M., Wentzel-Larsen T., Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006, 21:1123-1130.
6. Alcalay R.N., Mirelman A., Saunders-Pullman R., Tang M.X., Mejia Santana H., Raymond D., et al. Parkinson disease phenotype in ashkenazi jews with and without LRRK2 G2019S mutations. Mov Disord 2013, 28(14):1966-1971.
7. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatry 1992, 55:181-184.
8. Mirelman A., Heman T., Yasinovsky K., Thaler A., Gurevich T., Marder K., et al. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation. Mov Disord 2013, 28:1683-1690.
9. Fahn S., Elton R. Members of the UPDRS development committee. The unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, vol. 2:153-163. Macmillan Healthcare Information, Florham Park, NJ, 293-304.
10. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology 1990, 40:1529-1534.
11. Mito Y., Yoshida K., Yabe I., Makino K., Tashiro K., Kikuchi S., et al. Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's disease. JNeurol Sci 2006, 241:67-72.
12. Burn D.J., Rowan E.N., Allan L.M., Molloy S., O'Brien J.T., McKeith I.G. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with lewy bodies. JNeurol Neurosurg Psychiatry 2006, 77:585-589.
13. Taylor J.P., Rowan E.N., Lett D., O'Brien J.T., McKeith I.G., Burn D.J. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. JNeurol Neurosurg Psychiatry 2008, 79:1318-1323.
14. Muslimovic D., Post B., Speelman J.D., De Haan R.J., Schmand B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. JInt Neuropsychol Soc 2009, 15:426-437.
15. Muslimovic D., Post B., Speelman J.D., Schmand B. Cognitive profile of patientswith newly diagnosed Parkinson disease. Neurology 2005, 65:1239-1245.
16. Caccappolo E., Alcalay R.N., Mejia-Santana H., Tang M.X., Rakitin B., Rosado L., et al. Neuropsychological profile of Parkin mutation carriers with and without Parkinson disease: the CORE-PD study. JInt Neuropsychol Soc 2011, 17:91-100.
17. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.X., Rosado L., Orbe Reilly M., et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012, 78:1434-1440.
18. Alcalay R.N., Mejia-Santana H., Tang M.X., Rakitin B., Rosado L., Ross B., et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. JClin Exp Neuropsychol 2010, 32:775-779.
19. Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J., Hulihan M., White L., et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005, 57:762-765.
20. Ben Sassi S., Nabli F., Hentati E., Nahdi H., Trabelsi M., Ben Ayed H., et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Park Relat Disord 2012, 18:243-246.
21. Belarbi S., Hecham N., Lesage S., Kediha M., Smail N., Benhassine T., et al. LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Park Relat Disord 2010, 16:676-679.
22. Shanker V., Groves M., Heiman G., Palmese C., Saunders-Pullman R., Ozerlius L., et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord 2011, 26:1875-1880.
23. Lohmann E., Leclere L., De Anna F., Lesage S., Dubois B., Agid Y., et al. Aclinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. Park Relat Disord 2009, 15:273-276.
24. Goldwurm S., Zini M., Di Fonzo A., De Gaspari D., Siri C., Simons E.J., et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Park Relat Disord 2006, 12:410-419.
25. Thaler A., Mirelman A., Helmich R.C., van Nuenen B.F., Rosenberg-Katz K., Gurevich T., et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 2013, 49:2501-2511. a journal devoted to the study of the nervous system and behavior. http://www.ncbi.nlm.nih.gov/pubmed/23357204.
26. van Nuenen B.F., Helmich R.C., Ferraye M., Thaler A., Hendler T., Orr-Urtreger A., et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012, 135:3687-3698.
27. Irwin D.J., White M.T., Toledo J.B., Xie S.X., Robinson J.L., Van Deerlin V., et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012, 72:587-598.
28. Marder K., Tang M.X., Cote L., Stern Y., Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995, 52:695-701.
29. Factor S.A., Steenland N.K., Higgins D.S., Molho E.S., Kay D.M., Montimurro J., et al. Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. JNeurol Neurosurg Psychiatry 2011, 82:564-568.
30. Aarsland D., Kvaloy J.T., Andersen K., Larsen J.P., Tang M.X., Lolk A., et al. The effect of age of onset of PD on risk of dementia. JNeurol 2007, 254:38-45.
31. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.X., Rosado L., Orbe Reilly M., et al. Cognitive and motor function in long-duration parkin-associated Parkinson disease. JAMA Neurol 2014, 71(1):62-67.
32. Poulopoulos M., Levy O.A., Alcalay R.N. The neuropathology of genetic Parkinson's disease. Mov Disord 2012, 27:831-842.
33. Poulopoulos M., Cortes E., Vonsattel J.P.G., Fahn S., Waters C., Cote L., et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. JMol Neurosci 2012, 47:139-143.
34. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.X., Rosado L., Ross B.M., et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010, 67:1116-1122.